01:21 PM EDT, 07/16/2025 (MT Newswires) -- (Updates with stock price movement in the headline and first paragraph.)

Madrigal Pharmaceuticals ( MDGL ) shares were up more than 12% in recent trading Wednesday after the company said it received a Notice of Allowance from the US Patent and Trademark Office for its Rezdiffra treatment.

The therapy is for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis.

Once granted, a patent will be valid until Sept. 30, 2044, and will be listed in the US Food and Drug Administration's Orange Book, the company said.

Price: 349.09, Change: +37.95, Percent Change: +12.20